Steve joined Venrock in 2007 after spending nine years as CEO of Venrock-backed materials science company Symyx Technologies. He serves on the Board of Directors of Nanosys, Qteros and Sapphire Energy. Previously, he served on the Boards of Affymax (acquired by GlaxoSmithKline), Aspect Development (acquired by i2 Technologies), Ilypsa (acquired by Amgen), Intermolecular, One Touch Systems (acquired by Apollo Group), PeopleSoft (acquired by Oracle), Scientific Software (acquired by Agilent), Scios (acquired by Johnson & Johnson), TGV (acquired by Cisco) and Vitae Pharmaceuticals.
Prior to Symyx, Steve served as the CEO of MDL Information Systems, a leading scientific information company, before its sale to Reed Elsevier. Prior to MDL, he held various management positions at Alza Corporation (acquired by Johnson and Johnson), including President of Alza Pharmaceuticals. Steve was also President of Dynapol, a specialty chemical company and is a registered patent attorney.
Steve earned an A.B. in Chemistry from the University of North Carolina and a J.D. from Georgetown University Law Center.